Pharmacoeconomical analysis of inhaled glucocorticosteroids in the treatment of children with cough variant asthma
10.3760/cma.j.issn.1008-6706.2016.16.010
- VernacularTitle:吸入型糖皮质激素治疗儿童咳嗽变异性哮喘的药物经济学分析
- Author:
Cuibing LI
;
Suichen CHEN
- Publication Type:Journal Article
- Keywords:
Glucocorticoids;
Metered Dose Inhalers;
Anti -Asthmatic Agents;
Child;
Economics,Pharmaceutical;
Costs and Cost Analysis
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(16):2438-2441
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the clinical curative effect and pharmacoeconomics of inhaled glucocortico-steroids(ICS)in the treatment of children with cough variant asthma(CVA),in order to provide the reference for reasonable and economic drug -use of clinic treating children with CVA.Methods 128 children with CVA were divided into A,B,C three groups according to random number table method in our hospital from March 2013 to May 2014.The children with CVA of A,B,C groups were respectively given budesonide aerosol(200 -800μg/day,twice per day),fluticasone propionate aerosol(50 -100μg/time,twice per day),beclometasone dipropionate aerosol(50 -100μg/time,three times per day)on the basis of bronchodilator,smooth wheezing and expectorant.The clinical effica-cy and cost -effectiveness was evaluated after 12 weeks of treatment.Results The clinical total effective rates of A, B,C group were 90.0%,93.4%,90.7% respectively,and there were no statistically significant difference(χ2 =25.215,22.878,21.336,all P >0.05 ).The per capita cost of A,B,C group were 498.68yuan,671.20yuan, 541.14yuan respectively,and A group had the lowest cost -effectiveness ratio(C /E =5.54).Conclusion Budes-onide aerosol has better economy in treating of children with CVA.
